Press coverage about BioTelemetry (NASDAQ:BEAT) has trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. BioTelemetry earned a daily sentiment score of 0.10 on Accern’s scale. Accern also assigned news headlines about the medical research company an impact score of 46.563966324326 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:

Shares of NASDAQ:BEAT traded up $1.80 on Friday, reaching $62.05. The company had a trading volume of 506,494 shares, compared to its average volume of 350,890. The company has a current ratio of 2.29, a quick ratio of 2.12 and a debt-to-equity ratio of 0.72. The company has a market capitalization of $1.93 billion, a PE ratio of 44.17, a P/E/G ratio of 3.90 and a beta of 1.46. BioTelemetry has a 52-week low of $23.30 and a 52-week high of $62.80.

BioTelemetry (NASDAQ:BEAT) last posted its quarterly earnings data on Wednesday, July 25th. The medical research company reported $0.46 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.31 by $0.15. BioTelemetry had a positive return on equity of 18.02% and a negative net margin of 0.39%. The firm had revenue of $101.36 million during the quarter, compared to analysts’ expectations of $95.87 million. During the same quarter last year, the firm earned $0.23 EPS. The business’s quarterly revenue was up 74.4% on a year-over-year basis. research analysts predict that BioTelemetry will post 1.51 EPS for the current year.

BEAT has been the subject of several analyst reports. SunTrust Banks raised their price objective on BioTelemetry to $67.00 and gave the company a “buy” rating in a research note on Friday, August 31st. Zacks Investment Research raised BioTelemetry from a “hold” rating to a “buy” rating and set a $51.00 price target for the company in a research note on Tuesday, June 26th. Raymond James raised their price target on BioTelemetry from $57.00 to $66.00 and gave the stock an “outperform” rating in a research note on Friday. Benchmark raised their price objective on BioTelemetry from $46.00 to $54.00 and gave the stock a “buy” rating in a report on Wednesday, June 20th. Finally, TheStreet upgraded BioTelemetry from a “c” rating to a “b-” rating in a report on Tuesday, May 29th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $61.50.

In other news, SVP Daniel Wisniewski sold 31,000 shares of the business’s stock in a transaction dated Friday, August 31st. The stock was sold at an average price of $60.45, for a total value of $1,873,950.00. Following the completion of the transaction, the senior vice president now owns 57,291 shares of the company’s stock, valued at approximately $3,463,240.95. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Joseph H. Capper sold 300,000 shares of the business’s stock in a transaction dated Friday, July 27th. The shares were sold at an average price of $53.92, for a total value of $16,176,000.00. Following the completion of the transaction, the chief executive officer now directly owns 387,509 shares of the company’s stock, valued at approximately $20,894,485.28. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 346,000 shares of company stock valued at $18,771,675. 9.60% of the stock is currently owned by insiders.

BioTelemetry Company Profile

BioTelemetry, Inc, a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology.

Further Reading: Leveraged Buyout (LBO)

Insider Buying and Selling by Quarter for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.